We're looking forward to Parent Project Muscular Dystrophy (PPMD)'s Annual Conference in Dallas. This important event is a highlight for our team and we’re proud to be a Platinum sponsor. Join our Chief Medical Officer Nerissa Kreher who will present on Friday! #PPMDconference

Entrada Therapeutics is participating in the Philly Cell and Gene Therapy Annual Conference in PA from June 23-24, 2023. Catch a presentation by Leo Qian, Co-Founder & VP, Discovery Research, on June 24: bit.ly/41E8TTD. #BiotechNews #EntradaHere

Entrada team members Phallika Mon and Prashant Singh attended the 17th #WRIB2023 last week, where they joined over 1000 professionals from biotech companies, CROs and regulatory agencies to discuss current topics in bioanalysis.

Last Friday, we welcomed Keygan Miller (Public Training Manager The Trevor Project) to discuss intersectionality and bias, empathetic listening and actionable allyship. Thank you to all who attended our workshop! #EntradaHere #Pride2023 #Inclusivity 🏳️‍🌈🏳️‍⚧️

Only 3 days left to apply for the Entrada DREAMS Grant Program! Submit your application by June 30th for a chance at one of three $25,000 grants. Apply now: entradatx.com/dreams. #EntradaDREAMS #GrantProgram #DiversityMatters

We’re committed to supporting our employees on their career journey, and sometimes that means leaving Entrada. We are proud of our newest #Entrada Alumni who are beginning advanced degrees at Ohio State and Cornell University. Congratulations to Sriya Sreekanth and Alec Goffin!

Wishing all of our Entrada family and friends a safe, happy and relaxing 4th of July! #IndependenceDay #FourthofJuly #4DayWeekend

We're proud to announce the publication of our manuscript titled "Endosomal Escape Vehicle Platform Enhances Oligonucleotide Delivery in Neuromuscular Disorders" in Molecular Therapy Family of Journals. Congrats to the Entrada team on this significant achievement! #EntradaHere #Duchenne

Our CMO Nerissa Kreher shared our exon-skipping programs for people living with Duchenne who are exon 44 or exon 45 skip amenable Parent Project Muscular Dystrophy (PPMD)'s conference. Thank you to all who participated, your insights are invaluable. #PPMDConference #DuchenneResearch #DMD

We’re proud to be building a company where everyone can belong, contribute and grow. Learn more about the values that bind us together below👇🏿👇🏻👇🏾👇🏽#EntradaHere

Our teammates Ashweta Sahni, PhD, and Matt Streeter, PhD, presented at #APS2023. View a copy of the poster presentation: bit.ly/41E8TTD.

Last week, 130+ team members celebrated our progress and team spirit on a memorable company boat trip, connecting outside the lab and enjoying laughter on the Boston Harbor. Join us in making a difference in patients' lives: entradatx.com/careers. #Biotech #EntradaHere

We're honored to have Nerissa Kreher, Chief Medical Officer, and Regan Sherman, Head of Patient Advocacy, representing Entrada at #CPOSummit. See the full agenda and stay tuned for updates: bit.ly/43obAZp. #patientadvocacy #CPO

We prioritize employee well-being by providing the invaluable benefit of Wellthy, a comprehensive Caregiver Concierge service. Find peace of mind with financial, medical, legal and social/emotional support: bit.ly/3izVZVa. #EntradaHere

We are delighted to continue the tradition of spotlighting our incredible summer interns. Meet Trude Davis, HR & Patient Advocacy Intern, who is a rising senior at Temple University studying Health Professions. #EntradaHere #TempleMade

#ICYMI, Entrada unveiled our new headquarters at the Innovation and Design Building in Boston Seaport! Our state-of-the-art lab and office space foster innovation, collaboration and creativity. Join us: bit.ly/3oLVc3b. #BiotechNews #EntradaHere

Today marks a significant milestone as we received authorization to initiate a Phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy in the United Kingdom. bit.ly/3YcYkWN #BiotechNews $TRDA

We announced second quarter 2023 financial results today which highlighted our recent approval to initiate a Phase 1 clinical trial for ENTR-601-44 in the United Kingdom as well as the extension of our cash runway through 2025. bit.ly/3Yt0Msn #BiotechNews $TRDA

We’re excited to welcome Gina Chapman to our Board of Directors! Gina’s expertise and proven track record of advancing therapeutics into the market will be crucial as we continue to progress Entrada’s expanding pipeline of intracellular therapeutics. bit.ly/3DRqzRo $TRDA

We're moving to LinkedIn!  You can continue to follow our updates and news here: linkedin.com/company/272027…. #Biotech #EntradaHere #LinkedIn